ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. Eric Weisblum, CEO of Silo Pharma commented “The successful results of our study show that the…


Previous articleOptimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre
Next articlePT337 – Lauren Katalinich & Anya Oleksiuk – The Psychedelic Society: The Power of Community and The Color of Teal